R&D at Almirall

We aim to bring breakthrough innovation in the field of dermatology to address patient’s unmet needs

Blending internal capabilities and know-how with our partner’s skills, we ensure that we came up with solutions that offer the best approach to dealing with every disease. Inspired by science and devoted to the patient. This is the best way to ensure the long-term fulfilment of our Noble Purpose.

Our Purpose

Our therapeutic focus

Medical dermatology with specific conditions and a substantial unmet need.

Our Legacy

Almirall history of more than 50 years doing R&D is reflected in the number of therapeutic solutions that have been brought to the market in several therapeutic areas over the years.

Aclidinium bromide
Aceclofenac
Almagate
Almotriptan

Cinitapride
Clebopride
Ebastine

These treatments contribute to improve the lives of millions of people worldwide across more than 70 countries.

A global footprint through our drugs

(*) Respiratory Franchise worldwide rights transferred to AstraZeneca in 2014.

Our capabilities

At Almirall we devote relevant efforts and resources to build and progress our pipeline of future products. We invest around from 10 to 12% of our annual net sales in R&D, devote 15 % of our workforce -260 scientists- and run three cutting edge R&D centers located in Spain, Germany and the US.

Meet the expert

Our pipeline

Our way of doing R&D marks our commitment

Commitment to patients

We test and we share. By providing accessible clinical trial information, we are committing to helping people - medical practitioners, patients and their families - improving their knowledge of healthcare testing and results.

Go to Clinical trials